Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance
Authors
Keywords
-
Journal
Cutaneous and Ocular Toxicology
Volume -, Issue -, Pages 1-18
Publisher
Informa UK Limited
Online
2022-02-03
DOI
10.1080/15569527.2022.2034842
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pembrolizumab-induced Stevens–Johnson Syndrome with Severe Ocular Complications
- (2021) Soyoung Ryu et al. OCULAR IMMUNOLOGY AND INFLAMMATION
- Sarcoid‐like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumab
- (2021) Shinkichi Takamori et al. Thoracic Cancer
- Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report
- (2021) Khashayar Esfahani et al. Journal for ImmunoTherapy of Cancer
- Skin autoimmunity might be associated with increased efficacy of atezolizumab in metastatic urothelial carcinoma: a case report
- (2020) Deni Rkman et al. CROATIAN MEDICAL JOURNAL
- Nivolumab-related lichen planus of the lip in a patient with head and neck cancer
- (2020) Panagiota Economopoulou et al. ORAL ONCOLOGY
- Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
- (2020) Fausto Petrelli et al. Cancers
- Psoriatic arthritis induced by anti-PD1 and treated with apremilast: a case report and review of the literature
- (2020) Olga Nigro et al. Immunotherapy
- Neutrophil‐predominant bullous pemphigoid induced by checkpoint inhibitors: A case series
- (2020) Lisa M. Morris et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Hypertrophic lichenoid dermatitis immune‐related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma
- (2020) Mario L. Marques‐Piubelli et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report
- (2020) Megumu Osaki et al. INVESTIGATIONAL NEW DRUGS
- Severe oral erosive lichenoid reaction to pembrolizumab therapy
- (2020) Indraneel Bhattacharyya et al. Oral Surgery Oral Medicine Oral Pathology Oral Radiology
- SINGLE-DOSE DURVALUMAB INDUCED SARCOIDOSIS-LIKE REACTION WITH GRANULOMA IN NON-SMALL CELL LUNG CANCER
- (2020) Philip Sobash et al. CHEST
- Pruritus and Tense Bullae After Discontinuation of Pembrolizumab in a Patient With Renal Cell Carcinoma
- (2020) Amy K. Bieber et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report
- (2020) Maria Anna Siciliano et al. Frontiers in Oncology
- Vitiligo-like depigmentation after pembrolizumab treatment in patients with non-small cell lung cancer: a case report
- (2020) Sook Jung Yun et al. Translational Lung Cancer Research
- Pembrolizumab‐induced vitiligo in a patient with lung adenocarcinoma: A case report
- (2020) Vedrana Bulat et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Anti-TIF1γ antibody-positive dermatomyositis in a 15-year-old boy with Epstein–Barr virus-related nasopharyngeal cancer receiving nivolumab
- (2020) Ryoko Asano et al. RHEUMATOLOGY
- Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers
- (2019) R. C. Liu et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Resolution of Pembrolizumab‐Associated Steroid‐Refractory Lichenoid Dermatitis with Cyclosporine
- (2019) Emma Fixsen et al. ONCOLOGIST
- Late-onset Stevens–Johnson syndrome due to nivolumab use for hepatocellular carcinoma
- (2019) Constantin A Dasanu JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review
- (2019) Hiroko Kadota et al. Current Rheumatology Reports
- Immune checkpoint inhibitors and their side effects
- (2019) Jennifer McLachlan PATHOLOGY
- Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma
- (2019) Elizabeth A. Blakeway et al. MELANOMA RESEARCH
- Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast
- (2019) Davide Fattore et al. EUROPEAN JOURNAL OF CANCER
- Bullous pemphigoid
- (2019) Denise Miyamoto et al. ANAIS BRASILEIROS DE DERMATOLOGIA
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy
- (2019) Daniel Johnson et al. Cancer Immunology Research
- An unusual skin reaction in uveal melanoma during treatment with nivolumab
- (2019) Giulia Veronesi et al. ANTI-CANCER DRUGS
- Bullous Lupus Under Nivolumab Treatment for Lung Cancer: A Case Report With Systematic Literature Review
- (2019) ALICIA WOUTERS et al. ANTICANCER RESEARCH
- Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report
- (2019) Michael A. Cardis et al. BMC CANCER
- A case of atezolizumab‐induced photodistributed bullous pemphigoid
- (2019) Erica Leavitt et al. Dermatologic Therapy
- Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus
- (2019) Marco Tagliamento et al. Immunotherapy
- First case of cutaneous sarcoidosis within tattoos under durvalumab
- (2019) Perrine M. Rousseau et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- A Severe, Refractory Case of Mucous Membrane Pemphigoid After Treatment With Pembrolizumab
- (2019) Letícia Mello Bezinelli et al. JOURNAL OF IMMUNOTHERAPY
- Dermatomyositis Part I: Clinical Features and Pathogenesis
- (2019) Madeline E. DeWane et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Pembrolizumab-Induced Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Metastatic Cervical Squamous Cell Carcinoma
- (2019) Shamika Robinson et al. AMERICAN JOURNAL OF DERMATOPATHOLOGY
- Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma
- (2019) Cory Kosche et al. MELANOMA RESEARCH
- Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid
- (2019) Christian D. Sadik et al. Frontiers in Immunology
- The impact of corticosteroid use during anti-PD1 treatment
- (2019) Eva Y Pan et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer
- (2019) Deniz C Guven et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Bullous pemphigoid associated with the 480-mg nivolumab dose in a patient with metastatic renal cell carcinoma
- (2019) Amruth Ratnakar Palla et al. Immunotherapy
- Pembrolizumab‐induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus
- (2019) Aimee Coscarart et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Bullous pemphigoid induced by pembrolizumab in a patient with non‐small‐cell lung cancer who achieved durable complete response despite treatment cessation and long‐term corticosteroid administration: A case report
- (2019) Yusuke Muto et al. JOURNAL OF DERMATOLOGY
- Oral Immune‐Related Adverse Events Associated with PD‐1 Inhibitor Therapy: A Case Series
- (2019) Muhammad Ali Shazib et al. ORAL DISEASES
- Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma
- (2019) Emilien Billon et al. Frontiers in Oncology
- Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus
- (2019) Misato Jono et al. INTERNAL MEDICINE
- Bullous Pemphigoid in a Patient Treated with Pembrolizumab
- (2019) Kanako Hara et al. INTERNAL MEDICINE
- Toxic epidermal necrolysis associated with pembrolizumab
- (2019) Zhuo Ran Cai et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Systemic Psoriasiform Dermatitis Appeared after the Administration of Pembrolizumab
- (2019) Manabu Suzuki et al. INTERNAL MEDICINE
- Pembrolizumab-associated Mucous Membrane Pemphigoid in a Merkel cell carcinoma patient
- (2018) V. Haug et al. BRITISH JOURNAL OF DERMATOLOGY
- A Case of Advanced Lung Adenocarcinoma with Nvolumab-associated Dermatomyositis
- (2018) Fumiaki Kudo et al. INTERNAL MEDICINE
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Erythema Nodosum as the Initial Presentation of Nivolumab-Induced Sarcoidosis-Like Reaction
- (2018) Alexandre Laroche et al. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
- Granulomatous and lichenoid dermatitis after IgG4 anti-PD-1 monoclonal antibody therapy for advanced cancer
- (2018) Julio A. Diaz-Perez et al. JOURNAL OF CUTANEOUS PATHOLOGY
- PD-1 Inhibitor-associated Myopathies
- (2018) Teerin Liewluck et al. JOURNAL OF IMMUNOTHERAPY
- Vitiligo-like lesions in patients receiving anti–programmed cell death-1 therapies are distinct from spontaneously occurring active vitiligo
- (2018) Katia Boniface et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy
- (2018) Jacob Siegel et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors
- (2018) Ioannis Gkiozos et al. Journal of Thoracic Oncology
- Sarcoid-like reactions in patients receiving modern melanoma treatment
- (2018) Florentia Dimitriou et al. MELANOMA RESEARCH
- A Case of Nivolumab‐Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein‐1/Programmed Death Ligand‐1 Inhibitors and Recommendations for Diagnosis and Management
- (2018) Adriana T. Lopez et al. ONCOLOGIST
- Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
- (2018) Shrujal Baxi et al. BMJ-British Medical Journal
- Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
- (2018) Shrujal Baxi et al. BMJ-British Medical Journal
- Nivolumab induced vitiligo-like lesions in a patient with metastatic squamous cell carcinoma of the lung
- (2018) Kazumi Nishino et al. Journal of Thoracic Disease
- Anti-programmed cell death-1-induced plaque and guttate psoriasis
- (2018) Toshiyuki Yamamoto INDIAN JOURNAL OF DERMATOLOGY
- Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment
- (2018) Léa Paolini et al. Journal for ImmunoTherapy of Cancer
- Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death (PD)-1 therapy
- (2018) A L Marano et al. BRITISH JOURNAL OF DERMATOLOGY
- Bullous pemphigoid and nivolumab: Dermatologic management to support and continue oncologic therapy
- (2018) Luigia Panariello et al. EUROPEAN JOURNAL OF CANCER
- Drug-induced oral lichenoid reaction during nivolumab therapy
- (2018) Y. Enomoto et al. INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
- Atypical pemphigus developed in a patient with urothelial carcinoma treated with nivolumab
- (2018) Michiko Ito et al. JOURNAL OF DERMATOLOGY
- Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy
- (2018) Andrew Hwang et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Management of Persistent Pruritus and Lichenoid Reaction Secondary to Nivolumab With Narrowband Ultraviolet B Phototherapy
- (2018) Marie Donaldson et al. Frontiers in Oncology
- Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma
- (2018) Mathilde Berger et al. EUROPEAN JOURNAL OF CANCER
- Atezolizumab-induced sarcoid-like granulomatous reaction in a patient with urothelial cell carcinoma
- (2018) Michael A Mitchell et al. Immunotherapy
- Vitiligo-like lesions in a patient treated with nivolumab for renal cell carcinoma
- (2018) Cristian Lolli et al. MEDICINE
- Subacute cutaneous lupus erythematosus induced by nivolumab
- (2018) Nesrine B. Zitouni et al. MELANOMA RESEARCH
- PD-1 Blockade–Induced Pruritus Treated with a Mu-Opioid Receptor Antagonist
- (2018) Shawn G. Kwatra et al. NEW ENGLAND JOURNAL OF MEDICINE
- Constitutional mismatch repair-deficiency: current problems and emerging therapeutic strategies
- (2018) Malak Abedalthagafi Oncotarget
- Pembrolizumab-induced Stevens–Johnson syndrome in non-melanoma patients
- (2017) Stephanie Saw et al. EUROPEAN JOURNAL OF CANCER
- Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis
- (2017) Anna J. Lomax et al. International Journal of Rheumatic Diseases
- Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy
- (2017) Karina L. Vivar et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy
- (2017) Kimberly Shao et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen XVII
- (2017) Naoko Wada et al. JOURNAL OF DERMATOLOGY
- Two cases of anti-programmed cell death 1-associated bullous pemphigoid-like disease and eruptive keratoacanthomas featuring combined histopathology
- (2017) J. P. Bandino et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings
- (2017) V. Sibaud et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Multiple erosive lichen planus preceded by solitary lichen planus after combination therapy with nivolumab and radiation
- (2017) T. Komori et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report
- (2017) Takeshi Uenami et al. LUNG CANCER
- Aprepitant for refractory nivolumab-induced pruritus
- (2017) Jiro Ito et al. LUNG CANCER
- Nivolumab Therapy for Treatment-Related Vitiligo in a Patient With Relapsed Metastatic Melanoma
- (2017) Yasuhiro Nakamura et al. JAMA Dermatology
- Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid
- (2017) Laura Sowerby et al. JAMA Dermatology
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Pulmonary sarcoid-like granulomatosis induced by nivolumab
- (2016) H. Montaudié et al. BRITISH JOURNAL OF DERMATOLOGY
- Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma
- (2016) François-Xavier Danlos et al. CHEST
- Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
- (2016) Vincent Sibaud et al. CURRENT OPINION IN ONCOLOGY
- Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
- (2016) V.R. Belum et al. EUROPEAN JOURNAL OF CANCER
- Anti-PD1-induced psoriasis: a study of 21 patients
- (2016) J. Bonigen et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab
- (2016) Adepitan A. Owosho et al. ORAL ONCOLOGY
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
- (2016) Camille Hua et al. JAMA Dermatology
- Dermatomyositis, polymyositis and immune-mediated necrotising myopathies
- (2015) Yue-Bei Luo et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab
- (2015) Giuliana Carlos et al. MELANOMA RESEARCH
- Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma
- (2015) Mikio Ohtsuka et al. JAMA Dermatology
- Pathogenesis of Dermatomyositis: Role of Cytokines and Interferon
- (2011) Lily Kao et al. Current Rheumatology Reports
- Lower expression levels of the programmed death 1 receptor on CD4+CD25+ T cells and correlation with the PD-1.3A genotype in patients with systemic lupus erythematosus
- (2010) Helga Kristjansdottir et al. ARTHRITIS AND RHEUMATISM
- The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis
- (2009) Antonella Di Cesare et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started